Zacks: Brokerages Expect Omeros Co. (OMER) Will Announce Earnings of -$0.12 Per Share
Equities research analysts predict that Omeros Co. (NASDAQ:OMER) will report earnings of ($0.12) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omeros’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.22). Omeros posted earnings per share of ($0.53) during the same quarter last year, which suggests a positive year-over-year growth rate of 77.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.78) to $0.17. For the next financial year, analysts anticipate that the business will post earnings of $0.81 per share, with EPS estimates ranging from ($0.96) to $2.57. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Omeros.
Omeros (NASDAQ:OMER) last posted its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.42 million. Omeros’s revenue was up 60.0% compared to the same quarter last year. During the same period last year, the business earned ($0.34) EPS.
OMER stock opened at $17.92 on Thursday. The firm has a market cap of $878.26 million, a price-to-earnings ratio of -8.07 and a beta of 3.60. Omeros has a 52-week low of $10.30 and a 52-week high of $27.00.
Several hedge funds and other institutional investors have recently modified their holdings of OMER. Millennium Management LLC grew its stake in shares of Omeros by 844.8% in the fourth quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock valued at $12,394,000 after buying an additional 994,829 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Omeros by 49.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock valued at $21,303,000 after buying an additional 632,840 shares in the last quarter. SG Americas Securities LLC purchased a new position in Omeros in the fourth quarter valued at $955,000. First Trust Advisors LP purchased a new position in Omeros in the fourth quarter valued at $879,000. Finally, Tibra Equities Europe Ltd purchased a new position in Omeros in the first quarter valued at $771,000. 49.19% of the stock is owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.